EMBRACE is a Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2.
Dr Katrin Sjoquist, Medical Oncologist
EMBRACE is a study of patients with metastatic triple negative breast cancer (TNBC) or relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC) after first line/adjuvant therapy who have an eligible tumour molecular analysis result are suitable for the trial.
Dr Katrin Sjoquist is the Study Chair for EMBRACE. The study is a collaboration between ANZGOG, Breast Cancer Trials (BCT), the Genomic Cancer Clinical Trials Initiative (GCCTI) and the NHMRC Clinical Trials Centre, University of Sydney.
Increasing evidence supports extent of BRCA 1 methylation as an important biomarker for response to PARP inhibitors (PARPi), and is potentially superior to other HRD markers. A prospective trial is critical to using this biomarker in clinical practice to identify those patients who will benefit most from PARPi.
We need your help to identify this small but important subgroup of patients.
There are currently 11 sites open in Australia:
- St George Hospital, NSW – Dr Katrin Sjoquist
- Royal Brisbane & Women’s Hospital, QLD – Dr Jeffrey Goh
- Peter MacCallum Cancer Centre, VIC – Dr Sumitra Ananda
- ICON, QLD – Dr Nicole McCarthy
- Royal Adelaide Hospital, SA – Dr Nick Murray
- Royal North Shore Hospital, NSW – Dr Sally Baron-Hay
- Coffs Harbour Health Campus, NSW – Dr Karen Briscoe
- Fiona Stanley Hospital, WA- Dr Andrew Redfern
- Border Medical Oncology, NSW – Dr Christopher Steer
- Pindara Private Hospital, QLD – Dr Marco Matos
- Ballarat Oncology & Haematology Clinical Trials Unit, VIC – Dr George Kannourakis
To refer patients please contact the EMBRACE team on embrace.study@sydney.edu.au
For more details please visit the ANZCTR website – ACTRN12617000855325
